Linked Life Data

21277298

Source:http://linkedlifedata.com/resource/pubmed/id/21277298

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2011-3-11
pubmed:abstractText
M(3) muscarinic receptors are localized on inflammatory cells, airway smooth muscle, and submucosal glands, known to mediate bronchoconstriction, mucus secretion, and airway remodeling. It is hypothesized bencycloquidium bromide (BCQB), a novel M(3) receptor antagonist, might have potential effects on airway hyperresponsiveness, inflammation and airway remodeling in a murine model of asthma. Mice sensitized and challenged with ovalbumin developed airway inflammation. Bronchoalveolar lavage fluid was examined to determine the total and differential cell counts, and cytokine levels. Lung tissues were evaluated for cell infiltration, mucus hypersecretion, airway remodeling, and the expression of inflammatory biomarkers. Airway hyperresponsiveness was monitored by direct airway resistance analysis. Inhalation administration of BCQB significantly not only reduced ovalbumin-induced airway hyperresponsiveness comparing to methacholine, and prevented the ovalbumin-induced increase in total cell counts and eosinophil counts. Reverse transcriptase polymerase chain reaction analysis of whole lung lysates revealed that BCQB markedly suppressed ovalbumin-induced mRNA expression of eotaxin, IL-5, IL-4 and MMP-9, and increased mRNA expression of IFN-? and TIMP-1 in a dose-dependent manner. Substantial IFN-?/IL-4 (Th1/Th2) levels were recovered in bronchoalveolar lavage fluid after BCQB treatment. In addition, histological studies showed that BCQB dramatically inhibited ovalbumin-induced lung tissue eosinophil infiltration, airway mucus production and collagen deposition in lung tissues. Results reported in current paper suggest that M(3) receptors antagonist may provide a novel therapeutic approach to treat airway inflammation, hyperresponsiveness and remodeling.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1879-0712
pubmed:author
pubmed:copyrightInfo
Crown Copyright © 2011. Published by Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
25
pubmed:volume
655
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
83-90
pubmed:meshHeading
pubmed-meshheading:21277298-Airway Remodeling, pubmed-meshheading:21277298-Animals, pubmed-meshheading:21277298-Bicyclo Compounds, Heterocyclic, pubmed-meshheading:21277298-Bronchoalveolar Lavage Fluid, pubmed-meshheading:21277298-Chemokines, pubmed-meshheading:21277298-Eosinophilia, pubmed-meshheading:21277298-Female, pubmed-meshheading:21277298-Gene Expression Regulation, pubmed-meshheading:21277298-Hypersensitivity, pubmed-meshheading:21277298-Inflammation, pubmed-meshheading:21277298-Lung, pubmed-meshheading:21277298-Matrix Metalloproteinases, pubmed-meshheading:21277298-Methacholine Chloride, pubmed-meshheading:21277298-Mice, pubmed-meshheading:21277298-Pneumonia, pubmed-meshheading:21277298-RNA, Messenger, pubmed-meshheading:21277298-Receptor, Muscarinic M3, pubmed-meshheading:21277298-Respiratory System
pubmed:year
2011
pubmed:articleTitle
M(3) muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice.
pubmed:affiliation
Zhejiang Respiratory Drugs Research Laboratory of State Food and Drug Administration of China, Medical College of Zhejiang University, Hangzhou, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't